Candel Therapeutics (NASDAQ:CADL) Receives Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Candel Therapeutics (NASDAQ:CADL) in a research report released on Monday,Benzinga reports. The brokerage currently has a $11.00 price objective on the stock.

Candel Therapeutics Stock Performance

Shares of NASDAQ CADL opened at $3.96 on Monday. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.62 and a current ratio of 1.62. The firm has a market cap of $126.88 million, a price-to-earnings ratio of -2.29 and a beta of -0.88. The business’s 50-day simple moving average is $6.01 and its 200-day simple moving average is $6.73. Candel Therapeutics has a 52 week low of $0.77 and a 52 week high of $14.30.

Insider Buying and Selling at Candel Therapeutics

In other Candel Therapeutics news, major shareholder Estuardo Aguilar-Cordova sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $6.02, for a total value of $90,300.00. Following the sale, the insider now owns 929,873 shares of the company’s stock, valued at $5,597,835.46. This trade represents a 1.59 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders have sold 31,800 shares of company stock valued at $193,380 in the last 90 days. 41.60% of the stock is currently owned by insiders.

Institutional Trading of Candel Therapeutics

A number of hedge funds have recently modified their holdings of the company. Point72 DIFC Ltd bought a new stake in shares of Candel Therapeutics in the 2nd quarter worth approximately $31,000. FMR LLC bought a new stake in shares of Candel Therapeutics in the 3rd quarter worth approximately $46,000. MetLife Investment Management LLC bought a new stake in shares of Candel Therapeutics in the 3rd quarter worth approximately $87,000. Atom Investors LP bought a new stake in shares of Candel Therapeutics in the 3rd quarter worth approximately $103,000. Finally, State Street Corp lifted its position in shares of Candel Therapeutics by 4.1% in the 3rd quarter. State Street Corp now owns 492,005 shares of the company’s stock worth $3,410,000 after acquiring an additional 19,207 shares during the period. Institutional investors own 13.93% of the company’s stock.

About Candel Therapeutics

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.